Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

Completed · Phase 3

Conditions studied: Lung Cancer, Non-Small Cell

In brief

The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition.

Key facts

Study ID

NCT00390806

Run by

GlaxoSmithKline

People needed

472

Starts

2006-12-01

Expected to finish

2013-09-01

Last updated by the study team

2014-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least one measurable cancerous lesion in the brain from primary non-small cell lung cancer (NSCLC)
• Must have received previous chemotherapy
• Must be 18 years of age of greater
• Must be Easter Cooperative Oncology Group (ECOG) Performance Status 0, 1, 2
• At least 2 weeks must have elapsed since any surgery
• At least 4 weeks must have elapsed since any radiation to a non-CNS site
• Must have adequate bone marrow, renal, and live capacities
• Women must be of non-childbearing potential or practice adequate birth control
• Males must practice adequate methods of birth control
• Must sign written informed consent

You may not qualify if…

• Previous whole brain radiation therapy
• Prior treatment with topotecan
• Investigational agent within 30 days or 5 half-live
• Concomitant therapy with inhibitors of breast cancer resistance protein (BCRP) or P-glycoprotein such as erlotinib or gefitinib
• Primary or secondary immunodeficiencies
• Gastrointestinal conditions that affect GI absorption or motility
• Uncontrolled emesis
• Brain metastasis at time of initial diagnosis of NSCLC
• History of other malignancy except in situ carcinoma of cervix; nonmelanomatous skin cancer, low grade prostate cancer
• Pregnant or intending to become pregnant or intending to father a baby
• Any severe concurrent medical condition that could affect compliance.

Where it is running

• GSK Investigational Site — Glendale, Arizona, United States
• GSK Investigational Site — Hot Springs, Arkansas, United States
• GSK Investigational Site — Anaheim, California, United States
• GSK Investigational Site — Duarte, California, United States
• GSK Investigational Site — Pleasant Hill, California, United States
• GSK Investigational Site — Aurora, Colorado, United States
• GSK Investigational Site — Lakeland, Florida, United States
• GSK Investigational Site — Tampa, Florida, United States
• GSK Investigational Site — Tampa, Florida, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Elk Grove Village, Illinois, United States
• GSK Investigational Site — Galesburg, Illinois, United States
• GSK Investigational Site — Park Ridge, Illinois, United States
• GSK Investigational Site — Rockford, Illinois, United States
• GSK Investigational Site — Skokie, Illinois, United States
• GSK Investigational Site — Indianapolis, Indiana, United States
• GSK Investigational Site — Westwood, Kansas, United States
• GSK Investigational Site — Paducah, Kentucky, United States
• GSK Investigational Site — Metairie, Louisiana, United States
• GSK Investigational Site — Minneapolis, Minnesota, United States
• GSK Investigational Site — Jackson, Mississippi, United States
• GSK Investigational Site — Columbia, Missouri, United States
• GSK Investigational Site — Kansas City, Missouri, United States
• GSK Investigational Site — Lincoln, Nebraska, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.